AZ’ HER2 drug hits mid-stage trial endpoints
The drug has been granted US FDA Breakthrough Therapy Designation and Fast Track Designation.
Read More
Author: Anna Smith
LifeArc receives $1.2b in Keytruda royalties
In 2016, LifeArc sold a small proportion of its Keytruda royalty interest for $150 million to a private equity fund.
Read More
Scancell, CR UK publish joint vaccine update
SCIB2 is to be administered using a new nanoparticle formulation in a planned Phase I/II clinical trial.
Read More
Vulnerable children stuck in mental health hospitals for too long
Too many children are being admitted to secure hospitals unnecessarily, and in some cases are spending months and years of their childhood in institutions.
Read More
Insilico, ARK initiate health-span and longevity partnership
The newly developed ‘ARK’ will develop a programme of events to facilitate networking in AI research across King’s.
Read More- FDA approves new high dose Spinraza regimen for SMA
- Viridian reports positive results from elegrobart phase 3 trial
- Cure Parkinson’s convenes expert panel to assess £2 million combination therapy funding call
- Kygevvi approved in Europe as first treatment for TK2d
- Tozorakimab shows significant benefit in two major COPD trials
